# A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

> **NCT06022029** · PHASE1 · RECRUITING · sponsor: **OncoNano Medicine, Inc.** · enrollment: 168 (estimated)

## Conditions studied

- Triple Negative Breast Cancer
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Lymphoma, Non-Hodgkin
- Mantle Cell Lymphoma
- Bladder Cancer
- Uveal Melanoma, Recurrent
- Cervix Cancer
- Carcinoma in Situ
- Head and Neck Squamous Cell Carcinoma
- Skin Cancer
- Metastatic Cancer
- Tumor, Solid
- Tumor Recurrence

## Interventions

- **DRUG:** ONM-501
- **DRUG:** Cemiplimab

## Key facts

- **NCT ID:** NCT06022029
- **Lead sponsor:** OncoNano Medicine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-13
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-08-29
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06022029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06022029, "A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06022029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*